Merck is acquiring Afferent Pharmaceuticals — including its therapeutic candidates targeting the P2X3 receptor, now in clinical testing for neurogenic conditions that include chronic respiratory diseases — under a definitive agreement announced by the two companies. A lead investigational drug developed by Afferent, AF-219, is under evaluation in a Phase 2b dose-escalating study (…
1. Find Information About Pulmonary Fibrosis It’s normal for patients to be overwhelmed by a diagnosis of pulmonary fibrosis (PF). PF is a respiratory disease that causes scarring or fibrosis in the lung tissue, and in most cases the causes are not fully understood. Being a rare condition, it’s…
Pulmonary fibrosis is a disease in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. Most of the time, the cause of how it develops is unknown and in these cases, it’s called idiopathic (unknown cause) pulmonary fibrosis. In this video, shared by the Institute…
A study from the Centre Hospitalier Universitaire de Liège at Sart Tilman recently reported that two growth factors, IGFBP-1 and IGFBP-2, are increased in the blood of untreated patients with idiopathic pulmonary fibrosis (IPF). People receiving treatment had lower IGFBP-2 levels that those who were not treated, indicating the factors might be…
Patients with idiopathic pulmonary fibrosis (IPF) often exhibit cardiovascular manifestations that affect patients’ morbidity and mortality according to the study”Cardiac manifestations of idiopathic pulmonary fibrosis,” published in Intractable and Rare Diseases Research. The authors reviewed evidence that links cardiovascular diseases to IPF and how the co-morbidities…
For people who live with idiopathic pulmonary fibrosis (IPF), traveling is not impossible, but it involves determined precautions and preparations. Traveling by plane can have respiratory implications so it is important that patients contact the airline beforehand to prevent any problems, as explained in this video by Professor Carlo Vancheri…
https://www.youtube.com/watch?v=axuIDgf1hkE Pulmonary fibrosis (PF) is a respiratory disease characterized by the formation of scarred tissue in the lungs, specifically in the air sacs known as alveoli. However, being a rare disease that affects about five million people throughout the world, pulmonary fibrosis is often away from the spotlight, which leads to…
What is idiopathic pulmonary fibrosis (IPF)? IPF is a rare lung disease in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. This scarring of the lung tissue causes IPF patients to experience severe difficulties in breathing among other serious symptoms. In this animated…
The Pulmonary Fibrosis Foundation (PFF) is a 501(c)(3) nonprofit organization focused on fighting pulmonary fibrosis (PF). But how did it all start? The brothers Albert Rose and Michael Rosenzweigh, PhD, watched their sister suffer from the rare lung condition, and they ended up being diagnosed with it as well,…
Pulmonary fibrosis is a disease in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. Most of the time, the cause of how it develops is unknown and in those cases, it’s called idiopathic (unknown cause) pulmonary fibrosis. In this video, shared by Institute of…
Get regular updates to your inbox.
